NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

NCT07309289 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

144

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer (CRC)

Interventions

DRUG: NALIRIFOX plus targeted therapy
DRUG: FOLFOX plus targeted therapy

Sponsor

Shanghai Zhongshan Hospital